Click here to close now.




















Welcome!

News Feed Item

Injectable Drug Delivery - Advances in Drug Delivery, Injection Devices and Technology (Conference, London)

 

DUBLIN, Mar. 20, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/sq2qm5/injectable_drug) has announced the addition of the "Injectable Drug Delivery - Advances in Drug Delivery, Injection Devices and Technology (Conference, London)" conference to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The Injectable Drug Delivery Conference will be held on the 26th & 27th March 2014 at Le Meridien Hotel, Piccadilly, London

KEY TOPICS TO INCLUDE:
- Market trends
- Human factors and useability
- Fluid dynamics - modelling the realities of injection performance
- Delivery of high viscosity drugs
- Case study presentation on devices in development
- Latest self injection trends
- Development of a parenteral device
- Delivery of high volumes
- Compliance modelling and parenteral drug delivery
- The insulet drug delivery system

DATES:

26 & 27 March 2014

TIMES:

Day One: 26 March 2013
Start times: 9.30 Finish 17.45

Drinks Reception Followed by Dinner 19.30

Day Two: 27 March 2013
Start times: 9.00 Finish 16.15

VENUE FOR CONFERENCE AND DINNER:

Le Meridien Hotel, Piccadilly, London

NOTE: Please note that there is a Pre-conference seminar on 25th March on 'Prefilled Syringes - Advances in Manufacture' and also a Post Conference Workshop on 28th March on 'Human Factors and Usability Engineering in the development of drug delivery products'.

Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged

Key Topics Covered:

INJECTABLE DRUG DELIVERY DAY ONE - 26 March 2013

09.30 - Chairman's Welcome and Introduction
Dr Gregory Berman,
Head of Innovation and Technology Management Group, Sagentia, UK

09.40 - Key Note Address: Market Trends

- High concentration formulations

- Larger doses, less frequent injections
Mathias Romacker, Drug Delivery Devices and Business Development, Amgen, USA

10.20 - Human Factors and Useability

- Ethonographic research on atuoinjector use for chronic conditions

- Relationship between a disease and its therapy - emotional and functional levels

- How this affects device selection
Mathew Young, CEO, Oval Medical Technologies Ltd, UK

11.00 - Discussion followed by Coffee

11.30 - Fluid Dynamics - Modelling the Realities of Injection Performance

- Mathematical modelling enables the opportunities and challenges of a range of device types to be explored early

- The implications of such characteristics as viscosity, dose volume and injection frequency are inseparable from the choice of delivery device

- Unfortunately, early consideration of the delivery device does not always take place. Opportunities can thus be lost and problems created which are costly and difficult to solve later

- Mathematical modelling techniques, applied properly, improve understanding of the issues concerned and enable better and earlier decisions to be taken

- Better informed decisions and better appreciations of the design options in turn support device designs which are better for the end user

- Early understanding of device issues supports and enables robust designs and capable manufacture

- Early understanding can shorten development timescales, in turn making earlier approval and earlier revenues possible
Andy Fry, Founder, Team Consulting, UK

12.10 - Delivery of High Viscosity Drugs

- Device formats

- Overcoming the challenges
Speaker, (invited)

12.50 - Discussion followed by Lunch

14.10 - Mixing Technologies for Reconstitution Devices

- Market Needs - Industry drivers and demands for these types of devices

- Latest mixing technologies

- Comparison of Lyophilised and Spray drying technologies

- Technical challenges with these types of devices
Tom Bailey, Managing Director, 3PInnovation, UK

14.50 - Device Case Study
Ian Anderson, Innovation Director, Bespak UK (invited)

15.30 - Discussion followed by Tea

16.10 - Latest Self Injection Trends

- General market trends

- Trends for biologics

- Trends for generics

- Pre-configured devices

- Future outlook
Mats Persson, Managing Director, SHL Group, Sweden

16.50 - Innovation in Primary Container Materials

- Trends for user requirements intended for self injection

- Material technology options and selection criteria

- Integration of Quality by Design for components

- Platform approach for lifecycle management
Tibor Hlobik, West Pharmaceutical Services

17.30 - Discussion

17.45 - End of Day One

19.30 - Drinks Reception Followed by Dinner at Le Meridien Hotel, London

INJECTABLE DRUG DELIVERY DAY TWO - 27 March 2013

09.00 - Review of Day One
Dr Gregory Berman,
Head of Innovation and Technology Management Group, Sagentia, UK

09.10 - What Does Pharma Want From its Drug Delivery Suppliers
Nick Bowman, Senior Director, Head of Devices COE, Pfizer, UK

09.50 - Pump Technology Case Study
Jonathan Rigby, President & CEO, SteadyMed Therapeutics Inc, USA, (invited)

10.30 - Discussion followed by Coffee

11.10 - Compliance Monitoring and Parenteral Drug Delivery

- Why is the industry suddenly talking about compliance and adherence monitoring (clinical trials and commercial applications)

- Advances in wireless communications enabling intelligent compliance monitoring

- The widespread availability of smart devices and their use in compliance monitoring, adherence and patient education

- Use of smartphone / smart devices apps for providing real-time information display and the potential for two way communications with the patient

- Regulatory issues associated with connected health systems and smartphone apps

- Using the cloud to store and disseminate data securely
Mark Tuckwell, Senior Consultant, Connected Health Systems,
Sagentia, UK

11.50 - Wireless Communication and Electronics for Compliance Monitoring

- Patient therapy compliance continues to be one of the biggest challenges in health systems

- 50% of all patients do not complete required treatment

- Reasons for the high rate of non-compliance

- Opportunities for medical manufacturers to offer innovative solutions

- Electronic compliance aids open interesting possibilities to remind, monitor and track patients' behavior, as well as to share vital therapy information with healthcare providers

- Key technologies that facilitate compliance, ranging from low-cost disposable electronics for dose counts and logs to a complete cloud-based system for monitoring compliance
Lior Shtram, Director, Design & Engineering, Flextronics Medical, Israel

12.30 - Discussion followed by Lunch

14.00 - Update on Regulations and Standards
Lee Leichter, President P/L Medical, USA

14.40 - The Insulet Drug Delivery System

Consists of two components
- Drug Delivery Pod
- Drug Delivery Manager

A Programmable, body worn, disposable, subcutaneous infusion pump

- Delivers up to 2ml of drug product over a three day period
- Delivery rate from 0.5 to 300 µl/hr
- Automated catheter insertion
- Waterproof (IPX8 25 feet for up to 60 minutes)

Provides the HCP and user maximum control, versatility, comfort and safety, while overcoming the numerous drawbacks of conventional infusion pump systems
Kevin Schmid, Vice President, Business Development & Advanced Technology Insulet Corporation, USA

15.20 - The Rise of the Bolus Injector

The changing needs of patients and new drugs are driving the growth of a new class of injection device: the large volume' or bolus' injector. This presentation will report the findings of a new research project run in collaboration with the Judge Business School, covering:

- The changing needs of patients and new drugs

- Could autoinjectors and infusion pumps meet the needs?

- Bolus injectors: a new class of injection device

- Example devices

- What to expect from the draft standard ISO 11608-6' on bolus injectors.
Tom Oakley, Director of Drug Delivery Device Development, Springboard, UK

16.00 - Discussion and Chairman's Closing Remarks

16.15 - End of Conference and Tea


For more information visit http://www.researchandmarkets.com/research/sq2qm5/injectable_drug



Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Providing the needed data for application development and testing is a huge headache for most organizations. The problems are often the same across companies - speed, quality, cost, and control. Provisioning data can take days or weeks, every time a refresh is required. Using dummy data leads to quality problems. Creating physical copies of large data sets and sending them to distributed teams of developers eats up expensive storage and bandwidth resources. And, all of these copies proliferating...
Malicious agents are moving faster than the speed of business. Even more worrisome, most companies are relying on legacy approaches to security that are no longer capable of meeting current threats. In the modern cloud, threat diversity is rapidly expanding, necessitating more sophisticated security protocols than those used in the past or in desktop environments. Yet companies are falling for cloud security myths that were truths at one time but have evolved out of existence.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...